157 related articles for article (PubMed ID: 37170423)
21. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
22. Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.
Wang EQ; Kaila N; Plowchalk D; Gibiansky L; Yunis C; Sweeney K
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):2013-2026. PubMed ID: 37994400
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia.
Jadhav SB; Amore BM; Bockbrader H; Crass RL; Chapel S; Sasiela WJ; Emery MG
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):351-364. PubMed ID: 37243877
[TBL] [Abstract][Full Text] [Related]
24. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
25. Statins for treatment of dyslipidemia in chronic kidney disease.
Shurraw S; Tonelli M
Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotide-mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice.
Bell TA; Liu M; Donner AJ; Lee RG; Mullick AE; Crooke RM
J Lipid Res; 2021; 62():100101. PubMed ID: 34371033
[TBL] [Abstract][Full Text] [Related]
27. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X; Peng DQ
Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia.
Tzeng TB; Schneck DW; Birmingham BK; Mitchell PD; Zhang H; Martin PD; Kung LP
Curr Med Res Opin; 2008 Sep; 24(9):2575-85. PubMed ID: 18674408
[TBL] [Abstract][Full Text] [Related]
29. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
30. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
31. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
32. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
[TBL] [Abstract][Full Text] [Related]
33. New Trends in Dyslipidemia Treatment.
Jang AY; Lim S; Jo SH; Han SH; Koh KK
Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
Li C; Shoji S; Beebe J
Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
[TBL] [Abstract][Full Text] [Related]
35. Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease.
Maroni L; Guasti L; Castiglioni L; Marino F; Contini S; Macchi V; De Leo A; Gaudio G; Tozzi M; Grandi AM; Cosentino M; Venco A
Am J Med Sci; 2011 Nov; 342(5):383-7. PubMed ID: 21629037
[TBL] [Abstract][Full Text] [Related]
36. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
37. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname MH; Rocha VZ; Santos RD
Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
39. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS).
Viigimaa M; Erglis A; Latkovskis G; Mäeots E; Petrulionienė Ž; Šlapikas R; Gocentiene A; Bramlage P; Brudi P
Medicina (Kaunas); 2014; 50(1):44-53. PubMed ID: 25060204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
